The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

pirarubicin     (7S,9R)-7-[(2S,4S,5S,6S)-4- amino-6-methyl...

Synonyms: CHEMBL1398373, AC1LCS5T, AKOS015895621, K234, ST51052919, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Therarubicin


High impact information on Therarubicin


Chemical compound and disease context of Therarubicin


Biological context of Therarubicin


Anatomical context of Therarubicin


Associations of Therarubicin with other chemical compounds


Gene context of Therarubicin


Analytical, diagnostic and therapeutic context of Therarubicin


  1. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Dhingra, K., Frye, D., Newman, R.A., Walters, R., Theriault, R., Fraschini, G., Smith, T., Buzdar, A., Hortobagyi, G.N. Clin. Cancer Res. (1995) [Pubmed]
  2. TRAIL and chemotherapeutic drugs in cancer therapy. Wu, X.X., Ogawa, O., Kakehi, Y. Vitam. Horm. (2004) [Pubmed]
  3. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma. Niitsu, N., Umeda, M. Leukemia (1998) [Pubmed]
  4. Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases. Ramirez, L.H., Munck, J.N., Bognel, C., Zhao, Z., Ardouin, P., Poupon, M.F., Gouyette, A., Rougier, P. Br. J. Cancer (1993) [Pubmed]
  5. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Marbeuf-Gueye, C., Broxterman, H.J., Dubru, F., Priebe, W., Garnier-Suillerot, A. Mol. Pharmacol. (1998) [Pubmed]
  6. Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and down-regulation of mdr1 gene expression. Belhoussine, R., Morjani, H., Lahlil, R., Manfait, M. Int. J. Cancer (1997) [Pubmed]
  7. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck. Nishioka, T., Tsuchiya, K., Nishioka, S., Kitahara, T., Ohmori, K., Homma, A., Aoyma, H., Shindoh, M., Shirato, H. Int. J. Radiat. Oncol. Biol. Phys. (2004) [Pubmed]
  8. First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising? Fakih, M. Ann. Oncol. (2004) [Pubmed]
  9. Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin. Herait, P., Poutignat, N., Marty, M., Bugat, R. Eur. J. Cancer (1992) [Pubmed]
  10. Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin's lymphoma. Takagi, T., Sakai, C., Oguro, M. Oncology (1990) [Pubmed]
  11. Effects of anthracycline derivatives on hepatic neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26. Iigo, M., Nishikata, K., Nakajima, Y., Hoshi, A. Br. J. Cancer (1991) [Pubmed]
  12. Apoptosis in young rats with adriamycin-induced cardiomyopathy--comparison with pirarubicin, a new anthracycline derivative. Koh, E., Ueda, Y., Nakamura, T., Kobayashi, A., Katsuta, S., Takahashi, H. Pediatr. Res. (2002) [Pubmed]
  13. Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium within sensitive and resistant cells. Fiallo, M., Laigle, A., Borrel, M.N., Garnier-Suillerot, A. Biochem. Pharmacol. (1993) [Pubmed]
  14. Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics. Marchiset-Leca, D., Leca, F.R., Galeani, A., Noble, A., Catalin, J. Cancer Chemother. Pharmacol. (1995) [Pubmed]
  15. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. Robert, J., Monnier, A., Poutignat, N., Hérait, P. Cancer Chemother. Pharmacol. (1991) [Pubmed]
  16. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. Sugiyama, T., Sadzuka, Y., Nagasawa, K., Ohnishi, N., Yokoyama, T., Sonobe, T. Jpn. J. Cancer Res. (1999) [Pubmed]
  17. Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte. Guerci, A., Lederlin, P., Reyes, F., Bordessoule, D., Sebban, C., Tilly, H., Kerneis, Y., Biron, P., Gisselbrecht, C., Herbrecht, R., Coiffier, B. Ann. Oncol. (1996) [Pubmed]
  18. Effect of anthracyclines on phospholipase A2 activity and prostaglandin E2 production in rat gastric mucosa. Grataroli, R., Leonardi, J., Chautan, M., Lafont, H., Nalbone, G. Biochem. Pharmacol. (1993) [Pubmed]
  19. Study of P-glycoprotein functionality in living resistant K562 cells after photolabeling with a verapamil analogue. Mankhetkorn, S., Teodori, E., Scapecchi, S., Garnier-Suillerot, A. Biochem. Pharmacol. (1996) [Pubmed]
  20. Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell lines. Nguyen, H.N., Sevin, B.U., Averette, H., Perras, J., Untch, M., Ramos, R., Donato, D., Penalver, M. Gynecol. Oncol. (1992) [Pubmed]
  21. Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells. Nagasawa, K., Ohnishi, N., Yokoyama, T. Jpn. J. Cancer Res. (1998) [Pubmed]
  22. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes. Mizutani, Y., Yoshida, O., Miki, T. J. Urol. (1999) [Pubmed]
  23. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Greish, K., Nagamitsu, A., Fang, J., Maeda, H. Bioconjug. Chem. (2005) [Pubmed]
  24. In vitro study of the compatibility of tris-acryl gelatin microspheres with various chemotherapeutic agents. Vallée, J.N., Lo, D., Guillevin, R., Reb, P., Adem, C., Chiras, J. Journal of vascular and interventional radiology : JVIR. (2003) [Pubmed]
  25. Non-Hodgkin's lymphoma developing in a pacemaker pocket. Hojo, N., Yakushijin, Y., Narumi, H., Minamoto, Y., Sakai, I., Takada, K., Hato, T., Yasukawa, M., Fujita, S. Int. J. Hematol. (2003) [Pubmed]
  26. Pancreatic cancer associated with granulocyte-colony stimulating factor production confirmed by immunohistochemistry. Ohtsubo, K., Mouri, H., Sakai, J., Akasofu, M., Yamaguchi, Y., Watanabe, H., Gabata, T., Motoo, Y., Okai, T., Sawabu, N. J. Clin. Gastroenterol. (1998) [Pubmed]
  27. The activity of latent benzoperimidine esters to inhibit P-glycoprotein and multidrug resistance-associated protein 1 dependent efflux of pirarubicin from several lines of multidrug resistant tumor cells. Głowacka-Rogacka, D., Arciemiuk, M., Kupiec, A., Bontemps-Gracz, M.M., Borowski, E., Tarasiuk, J. Cancer Detect. Prev. (2004) [Pubmed]
  28. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Reungpatthanaphong, P., Mankhetkorn, S. Biol. Pharm. Bull. (2002) [Pubmed]
  29. Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system. Hirano, S., Agata, N., Hara, Y., Iguchi, H., Shirai, M., Tone, H., Urakawa, N. Cancer Chemother. Pharmacol. (1991) [Pubmed]
  30. Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice. Favoulet, P., Benoit, L., Osmak, L., Polycarpe, E., Esquis, P., Duvillard, C., Guiu, B., Rat, P., Favre, J.P., Chauffert, B. World journal of surgery. (2004) [Pubmed]
  31. Phase II trial of pirarubicin in the treatment of advanced bladder cancer. Mahjoubi, M., Kattan, J., Ghosn, M., Droz, J.P., Philippot, I., Herait, P. Investigational new drugs. (1992) [Pubmed]
  32. Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model. Okada, M., Kudo, S., Miyazaki, O., Saino, T., Ekimoto, H., Iguchi, H., Hirano, S., Kuboki, H., Kadosawa, H., Takeuchi, T. Br. J. Cancer (1995) [Pubmed]
  33. Phase II clinical study of pirarubicin in hormone resistant prostate cancer. Rapoport, B.L., Falkson, G. Investigational new drugs. (1992) [Pubmed]
WikiGenes - Universities